OncoSil Selected for Major European Pancreatic Cancer Study
Filed with ASX · · 4 pages · English
Summary by 6ix AI
OncoSil Medical has been selected to participate in the PALACROS consortium, a significant European initiative aimed at improving outcomes for patients with locally advanced pancreatic cancer. The company will contribute through the PULSE Phase II clinical study, evaluating the effectiveness of repeat OncoSil treatments in patients following chemotherapy across multiple European centers. This participation is expected to yield substantial cost savings and provide access to valuable clinical data for regulatory and commercial purposes. The study aims to assess various endpoints, including survival rates and quality of life, which could enhance the adoption of OncoSil as a standard treatment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from OncoSil Medical
- OncoSil progresses HDE with US FDA
- OncoSil Medical Receives TGA Approval in Australia
- Security Class Reinstatement to Quotation - OSLOE
- Security Class Suspension from Quotation
- Appendix 4D and Half Year Accounts
Later from OncoSil Medical
- OncoSil Medical Files for FDA Approval
- OncoSil Medical Completes Manufacturing Validation
- Quarterly Activities/Appendix 4C Cash Flow Report
- OncoSil Receives FDA Approval for Distal Cholangiocarcinoma
- Investor Webinar Presentation
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical